Blood Journal
Leading the way in experimental and clinical research in hematology

Prostaglandin E2 enhances long-term repopulation but does not permanently alter inherent stem cell competitiveness

  1. Jonathan Hoggatt1,
  2. Khalid S. Mohammad2,
  3. Pratibha Singh1, and
  4. Louis M. Pelus1,*
  1. 1 Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, United States;
  2. 2 Medicine / Endocrinology, Indiana University School of Medicine, Indianapolis, IN, United States
  1. * Corresponding author; email: lpelus{at}iupui.edu

Key points

  • dmPGE2 treatment enhances long-term HSC repopulation without lineage bias or transformation

  • Treatment of HSC with dmPGE2 does not alter long-term competitiveness

Abstract

Hematopoietic stem cell (HSC) transplantation is a lifesaving therapy for malignant and non-malignant hematologic diseases and metabolic disorders. While successful, hematopoietic transplantation can be hindered by inadequate stem cell number, or poor engrafting efficiency. To overcome these deficits, we and others have previously reported the HSC enhancing ability of a short term exposure of prostaglandin E2 (PGE2) and this strategy has now progressed to phase I clinical trials in double cord blood transplantation. To further analyze the short and long-term effects of HSC exposure to PGE2, we followed the repopulation kinetics of PGE2 treated hematopoietic grafts through five serial transplantations and compared inherent long-term competitiveness in a HSC head-to-head secondary transplantation model. Treatment with PGE2 did not result in a long-term increase in HSC competitiveness, lineage bias or enhanced proliferative potential, demonstrating that pulse exposure to PGE2 results in transient increases in HSC homing and engraftment potential.

  • Submitted July 16, 2013.
  • Accepted September 9, 2013.